TR201718099A2 - Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar - Google Patents

Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar Download PDF

Info

Publication number
TR201718099A2
TR201718099A2 TR2017/18099A TR201718099A TR201718099A2 TR 201718099 A2 TR201718099 A2 TR 201718099A2 TR 2017/18099 A TR2017/18099 A TR 2017/18099A TR 201718099 A TR201718099 A TR 201718099A TR 201718099 A2 TR201718099 A2 TR 201718099A2
Authority
TR
Turkey
Prior art keywords
diclofenac
inflammation
pain
treatment
alkali metal
Prior art date
Application number
TR2017/18099A
Other languages
English (en)
Inventor
Nevzat Pi̇sak Mehmet
Original Assignee
Mehmet Nevzat Pisak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mehmet Nevzat Pisak filed Critical Mehmet Nevzat Pisak
Priority to TR2017/18099A priority Critical patent/TR201718099A2/tr
Priority to EA201991808A priority patent/EA201991808A1/ru
Priority to US16/497,571 priority patent/US20200022936A1/en
Priority to PCT/TR2018/050700 priority patent/WO2019098983A1/en
Priority to PCT/TR2018/050701 priority patent/WO2019098984A1/en
Publication of TR201718099A2 publication Critical patent/TR201718099A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

İleride belirtilenleri ihtiva eden bir kombinasyon: a) diklofenak veya onun farmasötik açıdan kabul edilebilir bir tuzu, b) tercihen famotidin veya onun farmasötik açıdan kabul edilebilir bir tuzu olmak üzere bir H2 reseptör antagonisti ve c) tercihen ağrı ve enflamasyon tedavisinde kullanıma yönelik potasyum bikarbonat olmak üzere bir alkali metal karbonat veya bikarbonat.
TR2017/18099A 2017-11-16 2017-11-16 Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar TR201718099A2 (tr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
TR2017/18099A TR201718099A2 (tr) 2017-11-16 2017-11-16 Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar
EA201991808A EA201991808A1 (ru) 2017-11-16 2018-11-16 Комбинации диклофенака, антагонистов н2 рецепторов и бикарбонатов щелочных металлов для лечения боли и воспаления
US16/497,571 US20200022936A1 (en) 2017-11-16 2018-11-16 Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation
PCT/TR2018/050700 WO2019098983A1 (en) 2017-11-16 2018-11-16 Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation
PCT/TR2018/050701 WO2019098984A1 (en) 2017-11-16 2018-11-16 Synergistic combination of diclofenac, famotidine and a carbonate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/18099A TR201718099A2 (tr) 2017-11-16 2017-11-16 Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar

Publications (1)

Publication Number Publication Date
TR201718099A2 true TR201718099A2 (tr) 2019-06-21

Family

ID=64949368

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/18099A TR201718099A2 (tr) 2017-11-16 2017-11-16 Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar

Country Status (4)

Country Link
US (1) US20200022936A1 (tr)
EA (1) EA201991808A1 (tr)
TR (1) TR201718099A2 (tr)
WO (2) WO2019098984A1 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020018048A2 (en) * 2018-05-28 2020-01-23 Pisak Mehmet Nevzat An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735369B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6974595B1 (en) * 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
AU2002305758B2 (en) 2001-06-01 2006-09-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2554012A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CN101511372B (zh) * 2006-07-07 2011-11-16 蒂尔坦制药有限公司 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
WO2012173581A1 (en) * 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Thiocolchicoside, etodolac and famotidine combinations

Also Published As

Publication number Publication date
WO2019098984A4 (en) 2019-06-20
EA201991808A1 (ru) 2019-12-30
WO2019098984A1 (en) 2019-05-23
WO2019098983A4 (en) 2019-06-20
US20200022936A1 (en) 2020-01-23
WO2019098983A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
UY38926A (es) INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
HK1245078A1 (zh) 治疗神经退行性疾病的方法
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
MX386699B (es) Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
MX376082B (es) Compuestos inhibidores de la señalizacion de la via de notch.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MX2024015576A (es) Tratamiento para migra?as
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
PE20171109A1 (es) Tratamientos medicos basados en anamorelina
FI3248597T3 (fi) Terapeuttinen aine sensorineuraaliseen kuulonmenetykseen
MX2020002741A (es) Uso de gaboxadol en el tratamiento de narcolepsia.
TR201718099A2 (tr) Ağri ve enflamasyonun tedavi̇si̇ i̇çi̇n di̇klofenak, h2 reseptör antagoni̇stleri̇ ve alkali̇ metal bi̇karbonatlarindan olusan kombi̇nasyonlar
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
PL3853219T3 (pl) Herbicydowo działające podstawione fenylopirymidynohydrazydy
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof